Cell Communication and Signaling is becoming the official journal of the Signal Transduction Society
- PDF / 125,774 Bytes
- 2 Pages / 610 x 792 pts Page_size
- 16 Downloads / 166 Views
BioMed Central
Open Access
Editorial
Cell Communication and Signaling is becoming the official journal of the Signal Transduction Society Stephan M Feller*1,2, Ralf Hass2,3, Ottmar Janssen2,4 and Karlheinz Friedrich2,5 Address: 1The Weatherall Institute of Molecular Medicine, University of Oxford, London, UK, 2Signal Transduction Society, Germany, 3Hannover Medical School (MHH), Hannover, Germany, 4Institute of Immunology, University of Kiel, Kiel, Germany and 5Institute of Biochemistry, University of Jena, Jena, Germany Email: Stephan M Feller* - [email protected]; Ralf Hass - [email protected]; Ottmar Janssen - [email protected]; Karlheinz Friedrich - [email protected] * Corresponding author
Published: 6 August 2008 Cell Communication and Signaling 2008, 6:1
doi:10.1186/1478-811X-6-1
Received: 1 July 2008 Accepted: 6 August 2008
This article is available from: http://www.biosignaling.com/content/6/1/1 © 2008 Feller et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Editorial The Signal Transduction Society (STS) [1] is delighted to join BioMed Central with an open access journal. Over the last years, our society members have increasingly appreciated that access to scientific information generated by publicly funded academic research must not be restricted by commercial interests. With overwhelming support of the society members, the presidial council and advisory board of the STS are therefore now taking action and moving from an access-restricted print journal to online open access publishing. We are convinced that unduly limiting the flow of scientific knowledge has a negative impact on the development of benefits for mankind and believe that BioMed Central is a highly valuable platform that is vital not only to scientists but to society in general and hence deserves our strong support. The need for free information flow within the academic community is especially true for rapidly evolving fields such as cell signaling, which is now entering a new and exciting era of development. The foundations in our molecular understanding, laid by numerous colleagues over the last decades, are now beginning to bear fruit in the form of an increasing number of targeted, signal transduction-modulating drugs entering clinical use. Over a dozen examples can be found in current cancer therapies alone, with more than a hundred further anti-cancer drug
candidates currently undergoing clinical evaluation. Nevertheless, much still needs to be done to improve the outcomes for countless severely suffering patients. Cell Communication and Signaling (CCS) and the STS are committed to playing an active part in the signal transduction research community by providing a stimulating and collegial forum for the speedy publication of state-of
Data Loading...
